Industry Sector: Biotechnology
AfaSci, Inc., a San Francisco Bay Area biotech, has been developing two therapeutic candidates with backup compounds for the treatment of neuropathic pain and neuroinflammatory pain, and pipeline for treatment of Alzheimer’s disease, epilepsy and sleep disorders. Both analgesic candidates are non-opioid, non-addictive and non-steroidal analgesics.
Our competitive advantage includes our drug candidates ready for IND-enabling studies, proprietary drug discovery platform, and all our projects were reviewed and supported by NIH grants. AfaSci has 4,200 square feet facility and well established in-house research capacity in electrophysiology and in vivo pharmacology. AfaSci received approval of NIH OLAW Assurance and established an IACUC for conducting animal research, and holds two active licenses of Schedule I and Schedule II-V control substances from DEA (Drug Enforcement Administration). AfaSci has broad academic collaboration including with Stanford University, Harvard University, UCLA, UC Davis and Kansas State University, etc. AfaSci is now seeking opportunities to advance our two drug candidates to IND and clinical development through licensing, joint development, or acquisition.